These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 8687151

  • 41. Parenteral nutrition support for patients with pancreatic cancer--improvement of the nutritional status and the therapeutic outcome.
    Richter E, Denecke A, Klapdor S, Klapdor R.
    Anticancer Res; 2012 May; 32(5):2111-8. PubMed ID: 22593497
    [Abstract] [Full Text] [Related]

  • 42. Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats.
    Kunze E, Schulz H, Ahrens H, Gabius HJ.
    Exp Toxicol Pathol; 1997 Aug; 49(3-4):167-80. PubMed ID: 9314050
    [Abstract] [Full Text] [Related]

  • 43. [Iscucin--mistletoe preparations for the pre- and postoperative treatment of malignancies. Documentation No. 21].
    Kast A, Hauser SP.
    Schweiz Rundsch Med Prax; 1990 Apr 03; 79(14):427-9. PubMed ID: 2343229
    [Abstract] [Full Text] [Related]

  • 44. [Vysorel/Isorel--cancer drug from Viscum album. Documentation No.20].
    Kast A, Hauser SP.
    Schweiz Rundsch Med Prax; 1990 Mar 13; 79(11):332-4. PubMed ID: 2315589
    [Abstract] [Full Text] [Related]

  • 45. Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin).
    Sperti C, Pasquali C, Catalini S, Cappellazzo F, Bonadimani B, Militello C, Pedrazzoli S.
    Eur J Surg Oncol; 1992 Jun 13; 18(3):267-71. PubMed ID: 1535051
    [Abstract] [Full Text] [Related]

  • 46. Recognition of different antigens of mistletoe extracts by anti-mistletoe lectin antibodies.
    Stein GM, Pfüller U, Berg PA.
    Cancer Lett; 1999 Jan 29; 135(2):165-70. PubMed ID: 10096425
    [Abstract] [Full Text] [Related]

  • 47. [Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients].
    Beuth J, Stoffel B, Ko HL, Buss G, Tunggal L, Pulverer G.
    Arzneimittelforschung; 1995 Apr 29; 45(4):505-7. PubMed ID: 7779151
    [Abstract] [Full Text] [Related]

  • 48. Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects.
    Huber R, Klein R, Berg PA, Lüdtke R, Werner M.
    J Altern Complement Med; 2002 Dec 29; 8(6):857-66. PubMed ID: 12614536
    [Abstract] [Full Text] [Related]

  • 49. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research.
    Stauder H, Kreuser ED.
    Onkologie; 2002 Aug 29; 25(4):374-80. PubMed ID: 12232491
    [Abstract] [Full Text] [Related]

  • 50. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.
    Tröger W, Galun D, Reif M, Schumann A, Stanković N, Milićević M.
    Dtsch Arztebl Int; 2014 Jul 21; 111(29-30):493-502, 33 p following 502. PubMed ID: 25142075
    [Abstract] [Full Text] [Related]

  • 51. Clinical relevance of immunoactive mistletoe lectin-I.
    Beuth J.
    Anticancer Drugs; 1997 Apr 21; 8 Suppl 1():S53-5. PubMed ID: 9179369
    [Abstract] [Full Text] [Related]

  • 52. [Effect of mistletoe lectin therapy on serum level of defined serum proteins (acute phase proteins) in tumor patients].
    Beuth J, Gabius HJ, Steuer MK, Geisel J, Steuer M, Ko HL, Pulverer G.
    Med Klin (Munich); 1993 May 15; 88(5):287-90. PubMed ID: 7687001
    [Abstract] [Full Text] [Related]

  • 53. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients.
    Heiny BM, Beuth J.
    Anticancer Res; 1994 May 15; 14(3B):1339-42. PubMed ID: 8067703
    [Abstract] [Full Text] [Related]

  • 54. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients.
    Bock PR, Hanisch J, Matthes H, Zänker KS.
    Inflamm Allergy Drug Targets; 2014 May 15; 13(2):105-11. PubMed ID: 24766319
    [Abstract] [Full Text] [Related]

  • 55. [Mistletoe therapy from the pharmacologic perspective].
    Hajto T, Hostanska K, Saller R.
    Forsch Komplementarmed; 1999 Aug 15; 6(4):186-94. PubMed ID: 10529578
    [Abstract] [Full Text] [Related]

  • 56. Mistletoe lectins: telomerase inhibitors in alternative cancer therapy.
    Li SS.
    Drug Discov Today; 2002 Sep 01; 7(17):896-7. PubMed ID: 12546929
    [No Abstract] [Full Text] [Related]

  • 57. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract.
    Eisenbraun J, Scheer R, Kröz M, Schad F, Huber R.
    Phytomedicine; 2011 Jan 15; 18(2-3):151-7. PubMed ID: 20724129
    [Abstract] [Full Text] [Related]

  • 58. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis.
    Ostermann T, Büssing A.
    Explore (NY); 2012 Jan 15; 8(5):277-81. PubMed ID: 22938746
    [Abstract] [Full Text] [Related]

  • 59. Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire.
    Kirchberger I, Wetzel D, Finger T.
    Qual Life Res; 2004 Mar 15; 13(2):463-79. PubMed ID: 15085919
    [Abstract] [Full Text] [Related]

  • 60. Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts.
    Stein GM, Stettin A, Schultze J, Berg PA.
    Anticancer Drugs; 1997 Apr 15; 8 Suppl 1():S57-9. PubMed ID: 9179370
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.